Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,279
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.70 | 5.10 | 0.06% |
| CAC 40 | 8,078.48 | 0.68 | 0.01% |
| DAX 40 | 25,407.11 | 1.53 | -0.01% |
| Dow JONES (US) | 51,457.79 | 370.83 | -0.72% |
| FTSE 100 | 10,684.88 | 10.37 | -0.10% |
| HKSE | 24,642.51 | 132.42 | 0.54% |
| NASDAQ | 26,817.49 | 251.23 | -0.93% |
| Nikkei 225 | 65,877.62 | 486.59 | -0.73% |
| NZX 50 Index | 13,830.68 | 19.57 | 0.14% |
| S&P 500 | 7,682.06 | 61.35 | -0.79% |
| S&P/ASX 200 | 8,679.70 | 14.70 | 0.17% |
| SSE Composite Index | 3,823.62 | 64.75 | -1.67% |